Skip to main content
CLLS
NASDAQ Life Sciences

Cellectis Posts $101.1M Nine-Month Loss, Books $26.8M Impairment on Pivot

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.33
Mkt Cap
$108.333M
52W Low
$0.881
52W High
$5.45
52W Position info
51% above low
Off High info
76% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

CLLS sits 51% above its 52-week low of $0.881 on light trading volume (0.4× avg).

Summary

Cellectis' Q3 interim report quantifies the September pivot: a $26.8 million impairment and $6.1 million of severance pushed the nine-month net loss to $101.1 million, while $146.5 million of cash and deposits is said to fund operations into the second half of 2028.


Key Events · Earnings and Guidance · CLLS

  • Nine-Month Loss Widens to $101.1M

    Net loss for the nine months ended September 30, 2026 was $101.1 million versus $41.3 million a year earlier, and revenue fell 76.4% to $14.8 million as AstraZeneca research activity slowed.

  • Pivot Costs $26.8M Impairment Plus Severance

    The strategic transformation produced a $26.8 million impairment on Raleigh and Paris assets ($2.1 million right-of-use, $24.8 million property, plant and equipment) and $6.1 million of severance provisions, with headcount expected to fall by up to 70%.

  • Cibus Lease Guarantee Becomes $9.2M Liability

    After NGCRE sued Cibus and Cellectis on September 9, 2026, the company booked a $9.4 million expected credit loss and carries a $9.2 million financial guarantee liability against an $18.8 million potential undiscounted exposure.

  • Runway Stated Into Second Half of 2028

    Cash and cash equivalents of $28.2 million plus $118.3 million of fixed-term deposits at September 30, 2026 are expected to fund operations into the second half of 2028 once the realignment is complete.


Analysis · CLLS · Life Sciences

The September pivot now carries a price tag: a $26.8 million write-down of the Raleigh and Paris facilities, $6.1 million of severance provisions, and a headcount cut of up to 70%. Those charges drove the nine-month net loss to $101.1 million from $41.3 million a year earlier, while revenue fell 76.4% to $14.8 million as AstraZeneca collaboration work slowed. Partly offsetting is a $9.4 million expected credit loss on the legacy Calyxt/Cibus lease guarantee, now a $9.2 million liability after the landlord sued in September. For the thesis, runway is what matters: $28.2 million of cash plus $118.3 million of fixed-term deposits is stated to fund operations into the second half of 2028, buying time for .HEAL-101 and .HEAL-201 without an immediate raise.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CLLS was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.3M. The 52-week trading range was $0.88 to $5.45. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CLLS - Latest Insights

CLLS
Sep 14, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.10
Real-time Price: $1.33 info
Change: -$0.770 (-37%) info
Market Cap: $108.333M info
CLLS
Aug 06, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.69
Real-time Price: $1.33 info
Change: -$1.36 (-51%) info
Market Cap: $108.333M info
CLLS
Jun 25, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.89
Real-time Price: $1.33 info
Change: -$1.56 (-54%) info
Market Cap: $108.333M info
CLLS
Jun 11, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.18
Real-time Price: $1.33 info
Change: -$1.85 (-58%) info
Market Cap: $108.333M info
CLLS
Jun 09, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.33
Real-time Price: $1.33 info
Change: -$2.00 (-60%) info
Market Cap: $108.333M info